Clorox (CLX) Tops Q4 EPS by 4c, Guides In-Line

Clorox (NYSE: CLX) reported Q4 EPS of $1.53, $0.04 better than the analyst estimate of $1.49. Revenue for the quarter came in at $1.65 billion versus the consensus estimate of $1.65 billion.

"I'm very pleased with the strong results our team delivered in the fourth quarter and fiscal year," said Clorox Chairman and CEO Benno Dorer. "Our strategy drove fourth-quarter sales growth in each of our segments, and resulted in total company sales growth in every quarter for the fiscal year. I\'m also pleased with the continued progress we\'re making in International, as the team has now delivered several consecutive quarters of sales and profit growth in the fiscal year."

Commenting on fiscal year 2018, Dorer said, "We feel good about our ability to deliver another year of solid sales and earnings growth, even as we anticipate a more competitive retail environment. We remain confident in our 2020 strategy and are staying the course. We\'ll continue to focus on delivering profitable growth, with a priority to reinforce superior consumer value behind strong investments in our differentiated products and brands."

GUIDANCE:

Clorox sees FY2018 EPS of $5.52-$5.72, versus the consensus of $5.69.

For earnings history and earnings-related data on Clorox (CLX) click here.

You May Also Be Interested In

• AbbVie updates 2026 EPS guidance after $291M IPR&D charge
• Vertex to acquire Crinetics Pharmaceuticals for $10 billion
• Morgan Stanley turns cautious on freight stocks despite stronger cycle outlook